This is a list of clinical trials and research protocols underway that will help us study thryoid malignancies and other endocrine neoplasias. If you would like to participate in one of the trials, please call the Information Line toll-free at 1-800-392-1611 or askMDAnderson at 1-877-632-6789. For information on other clinical trials, please visit MD Anderson's Clinical Trials website.
Last updated May 1, 2019
- Thyroid Cancer
- Pituitary Tumors
- Other Endocrine Neoplasias including solid tumors
- Other MD Anderson Clinical Trials relevant to Endocrine Neoplasia patients
Protocol 2016-0916: Atezolizumab Combinations with Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas
The goal of this clinical research study is to learn if adding atezolizumab to other treatments can help to control thyroid cancer (either anaplastic or poorly differentiated thyroid cancers). The safety of this drug will also be studied.
Protocol 2016-1136: Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study.
The goal of this clinical research study is to learn if the combination of pembrolizumab and lenvatinib can help to control differentiated thyroid cancer (DTC). The safety of this drug combination will also be studied.
Protocol 2015-0003: A Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination with Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers
The goal of this clinical research study is to determine the response rate at 6 months following treatment with 131I in combination with placebo or selumetinib for radioactive iodine avid (RAIA) recurrent and/or metastatic thyroid cancer.
Protocol 2005-0222: ACROSTUDY - A Multicenter, Post Marketing Surveillance Study of Somavert Therapy in Patients with Acromegaly in the US and Europe.
The goal of this clinical research study is to look at the safety and effectiveness of long-term pegvisomant treatment for acromegaly
Protocol 2017-0948: A Randomized Registry Trial of Adjuvant Mitotane vs. Mitotane with Cisplatin/Etoposide After Primary Surgical Resection of Localized Adrenocortical Carcinoma with High Risk of Recurrence (ADIUVO-2 Trial)
The goal of this clinical research study is to learn if mitotane alone or in combination with cisplatin and etoposide can help to control adrenocrotical carcinoma (ACC) in patients who are at a high risk of having the disease return after surgery.
Protocol 2016-0741: A Phase II Study to Evaluate the Effects of Cabozantinib in Patients with Unresectable/Metastatic Adrenocortical Carcinoma.
The goal of this clinical research study is to learn if cabozantinib can help to control unresectable (cannot be removed with surgery) or metastatic (has spread) adrenocortical carcinomas. The safety of this drug will also be studied.
Protocol 2014-0081: A Pilot Study to Evaluate the Effects of Cabozantinib in Patients with Unresectable Metastatic Pheochromocytomas and Paragangliomas
The goal of this clinical research study is to learn if cabozantinib can help to control advanced or metastatic pheochromocytoma or paraganglioma..
Protocol 2017-0202: A Phase 1 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity
The goal of Part 1 of this clinical research study is to find the highest tolerable dose of LOXO-292 that can be given to patients with non-small cell lung cancer (NSCLC), medullary thyroid cancer, and any other tumors that have the RET mutation (a type of genetic change). The goal of Part 2 of this clinical research study is to learn if the dose of LOXO-292 found in Part 1 can help to control the disease. The safety of LOXO-292 will also be studied in both parts. This is the first study using LOXO-292 in humans.
Protocol 2016-1007: A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
There are 2 parts to this clinical research study: Part 1 (dose escalation) and Part 2 (dose expansion). The goal of Part 1 is to find the highest tolerable dose of BLU-667 that can be given to patients with non-small cell lung cancer (NSCLC), thyroid cancer, and other advanced solid tumor cancers that is unresectable (cannot be removed with surgery). The goal of Part 2 is to confirm that the highest tolerable dose of BLU-667 found in Part 2 is safe. Researchers also want to learn if the study drug can help to control the disease. The safety of this drug will also be studied in both parts of the study. This is the first study using BLU-667 in humans.